Objective： To study the changes in cardiac function of rheumatoid arthritis （RA） patients and to observe the effect of Xinfeng Capsule （新风胶囊 XFC） on them. Methods： Sixty-eight RA patients were randomly assig...Objective： To study the changes in cardiac function of rheumatoid arthritis （RA） patients and to observe the effect of Xinfeng Capsule （新风胶囊 XFC） on them. Methods： Sixty-eight RA patients were randomly assigned to two groups by a lottery： 38 patients in the treatment group treated orally with XFC, 3 capsules, thrice a day, and 30 in the control group treated with Fengshi Gutong Capsule （风湿骨痛胶囊, FSGTC）, 4 capsules, twice a day, 30 days as one course of treatment, and two courses were given for both groups. A normal control （NC） group including 20 healthy subjects was set up. The clinical efficacy was compared between the two treated groups. The changes in cardiac function, including early diastolic peak flow velocity （E）, late diastolic peak flow velocity （A）, left ventricular fraction shortening （FS）, and E/ A, as well as uric acid （UA）, erythrocyte sedimentation rate （ESR）, α-acid glycoprotein （α-AGP）, and hypersensitive C-reaction protein （hs-CRP）, were observed. The regulation T cell was determined with flow cytometry. Results： （1） The total effective rate in the treatment group and the control group was 92.1% （35/38） and 70.0% （21/30）, respectively. Significant difference was shown between them （P〈0.05）. （2） Compared with those of the NC group, E peak, E/A ratio, and FS of RA patients were lower （P〈0.01）, while A peak was higher （P〈0.01）. Moreover, A peak of the treatment group after treatment was significantly lower （P〈0.05） and E/A ratio was significantly higher （P〈0.05） as compared with those of the control group. （3） The improvement in the treatment group in reducing UA and hs-CRP was superior to those of the control group （P〈0.05）. In addition, the improvement in α-AGP, CD4＋CD25＋ Treg, and CD4＋CD25＋CD12T Treg of the treatment group was obvious as compared with the control group, although the difference was not statistically significant. （Conclusions： The descenden展开更多
基金Supported by the National Key Discipline of Traditional Chinese Medicine Project for Bi Diseases[Administration of Traditional Chinese Medicine,China(2009) No.30]Program of Science and Technology Department of Anhui Province,China(No. 07010300204)Traditional Chinese Medicine Research Project of Health Department of Anhui Province,China(No. 2009ZY05)
文摘Objective： To study the changes in cardiac function of rheumatoid arthritis （RA） patients and to observe the effect of Xinfeng Capsule （新风胶囊 XFC） on them. Methods： Sixty-eight RA patients were randomly assigned to two groups by a lottery： 38 patients in the treatment group treated orally with XFC, 3 capsules, thrice a day, and 30 in the control group treated with Fengshi Gutong Capsule （风湿骨痛胶囊, FSGTC）, 4 capsules, twice a day, 30 days as one course of treatment, and two courses were given for both groups. A normal control （NC） group including 20 healthy subjects was set up. The clinical efficacy was compared between the two treated groups. The changes in cardiac function, including early diastolic peak flow velocity （E）, late diastolic peak flow velocity （A）, left ventricular fraction shortening （FS）, and E/ A, as well as uric acid （UA）, erythrocyte sedimentation rate （ESR）, α-acid glycoprotein （α-AGP）, and hypersensitive C-reaction protein （hs-CRP）, were observed. The regulation T cell was determined with flow cytometry. Results： （1） The total effective rate in the treatment group and the control group was 92.1% （35/38） and 70.0% （21/30）, respectively. Significant difference was shown between them （P〈0.05）. （2） Compared with those of the NC group, E peak, E/A ratio, and FS of RA patients were lower （P〈0.01）, while A peak was higher （P〈0.01）. Moreover, A peak of the treatment group after treatment was significantly lower （P〈0.05） and E/A ratio was significantly higher （P〈0.05） as compared with those of the control group. （3） The improvement in the treatment group in reducing UA and hs-CRP was superior to those of the control group （P〈0.05）. In addition, the improvement in α-AGP, CD4＋CD25＋ Treg, and CD4＋CD25＋CD12T Treg of the treatment group was obvious as compared with the control group, although the difference was not statistically significant. （Conclusions： The descenden
